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ABSTRACT
Objective This study aimed to assess if there is 
secondary care medical inertia towards coeliac disease 
(CD).
Design Group (1): Time from primary care presentation 
to diagnostic endoscopy was quantified in 151 adult 
patients with a positive endomysial antibody test and 
compared with 92 adult patients with histologically proven 
inflammatory bowel disease (IBD). Group (2): Across four 
hospitals, duodenal biopsy reports for suspected CD were 
reviewed (n=1423). Group (3): Clinical complexity was 
compared between known CD (n=102) and IBD (n=99) 
patients at their respective follow- up clinic appointments. 
Group (4): 50 gastroenterologists were questioned about 
their perspective on CD and IBD.
Results Group (1): Suspected coeliac patients waited 
significantly longer for diagnostic endoscopy following 
referral (48.5 (28–89) days) than suspected patients 
with IBD (34.5 (18–70) days; p=0.003). Group (2): 1423 
patients underwent diagnostic endoscopy for possible CD, 
with only 40.0% meeting guidelines to take four biopsies. 
Increased diagnosis of CD occurred if guidelines were 
followed (10.1% vs 4.6% p<0.0001). 12.4% of newly 
diagnosed CD patients had at least one non- diagnostic 
gastroscopy in the 5 years prior to diagnosis. Group (4): 
32.0% of gastroenterologists failed to identify that CD has 
greater prevalence in adults than IBD. Moreover, 36.0% of 
gastroenterologists felt that doctors were not required for 
the management of CD.
Conclusion Prolonged waiting times for endoscopy and 
inadequacies in biopsy technique were demonstrated 
suggesting medical inertia towards CD. However, this has 
to be balanced against rationalising care accordingly. A 
Coeliac UK National Patient Charter may standardise care 
across the UK.
INTRODUCTION
Global meta- analysis of screening studies for 
coeliac disease (CD) has shown a variable 
prevalence of around 1%,1–4 but the vast 
majority of these patients remain undiag-
nosed.1 5 6 Comparison of screening studies 
with point prevalence data has demonstrated 
that only an estimated one in four cases of 
CD are diagnosed in the UK,5 representing 
a significant undiagnosed burden. However, 
in other countries such as the USA, studies 
have reported this undiagnosed burden to be 
far greater at 80%–90%.7 8 There is variation 
between different nations in ability to detect 
the condition, with a particularly high level of 
confirmed diagnoses in Finland, as evidenced 
in the city of Tampere, where 0.75% of adults 
are diagnosed.1 9
Compounded with this undiagnosed 
burden, diagnostic delay is a key and widely 
reported issue facing modern management 
of CD.10–13 Delays in diagnosis can present in 
Summary box
What is already known about this subject?
 ► Diagnostic delay is a key issue facing modern man-
agement of coeliac disease (CD) while only one in 
four cases are estimated to be diagnosed.
 ► Delayed diagnosis of CD is associated with an in-
creased risk of complications from the disease and 
a worse quality of life.
What are the new findings?
 ► Patients with CD face greater delays at all wait 
intervals from referral to diagnostic endoscopy 
compared with patients with inflammatory bowel 
disease (IBD).
 ► The majority of endoscopists do not follow guide-
lines for diagnostic endoscopy for CD. This reduced 
diagnosis rates by over 50%.
 ► Questionnaire findings presented an attitude of 
medical inertia towards CD alone and in comparison 
to IBD.
 ► This is the first study to fully represent how medical 
inertia towards CD directly leads to increased diag-
nostic delay and likely missed diagnoses.
How might it impact on clinical practice in the 
foreseeable future?
 ► This study characterises and raises awareness of 
prominent medical inertia towards CD among sec-
ondary care clinicians and demonstrates the effects 
of this on diagnostic delay. Our findings advocate 
the need to combat this through lower thresholds 
for investigation, greater adherence to biopsy guide-
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both primary and secondary care and international liter-
ature reports a mean delay range of 9.7–12.8 years.14–17
Of particular concern, these delays persist despite 
improvements in factors such as serological test avail-
ability, ease of access to endoscopy and increasing public 
awareness of the condition.5 These long delays are espe-
cially worrying in context of the substantial improvement 
to quality of life associated with diagnosis.10 17 Despite 
this burden of missed diagnoses and diagnostic delay, 
the incidence of CD continues to rise, with a fourfold 
increase in incidence seen in the UK between 1990 and 
2011,5 overall representing an increasing public health 
problem.
Delayed diagnosis of CD is correlated with increased 
risk of complications such as osteoporosis, peripheral 
neuropathy, microcytic (iron deficiency) and macro-
cytic (folate deficiency) anaemia, lymphoma (enterop-
athy associated T- cell lymphoma and other non- hodgkin 
lymphomas), hyposplenism, micronutrient deficiencies 
and increased rates of anxiety and depression.12 18 Impor-
tantly, earlier diagnosis is associated with lower stan-
dardised mortality ratios,19 20 while undiagnosed CD is 
associated with a worse quality of life which improves 
substantially on diagnosis.10 17 Prompt management with 
a strict gluten- free diet (GFD) leads to a rapid reduction 
in symptoms and reduced risk of malignancy (specifically 
gastrointestinal carcinoma or lymphoma).12 18
Previous studies investigating the cause of such delay 
and undiagnosed burden have hypothesised reasons 
such as patient related factors,11 to inability by clinicians 
to recognise the extraintestinal symptoms as indica-
tions for serological testing.8 21 More recently, the focus 
on causes of delay has centred around clinician factors 
such as medical inertia towards the condition by primary 
care physicians and inadequacies in biopsy technique 
in diagnosis of the condition. A study of primary care 
physicians in the USA found only 60% would perform 
serological testing for a young caucasian man with unex-
plained IDA while 80% said they would start a serologi-
cally positive patient on a GFD prior to endoscopy. This 
suggests a failure to recognise the pervasiveness of CD 
and a lack of clinical knowledge in how to properly 
approach diagnosing the condition, suggesting a level 
of medical inertia towards it.22 Meanwhile, studies exam-
ining previous endoscopies in patients with CD demon-
strated a failure to complete biopsies or take an adequate 
number of biopsy samples despite presence of symptoms 
suggestive of CD prior to diagnosis, resulting in delayed 
diagnoses.23 24
In attempts to deal with these issues of delayed and 
missed diagnoses, guidelines for the management of 
CD are constantly updated to account for the evolving 
knowledge base on this disease. Current National Insti-
tute for Health and Care Excellence (NICE) guidelines 
recommend that patients referred with suspected CD 
have a duodenal biopsy within 6 weeks of referral and 
that the patient is strongly encouraged to eat gluten in 
more than one meal a day for at least 6 weeks before the 
procedure.25 This may prove problematic for patients 
who have self- diagnosed themselves with CD and are 
already abstaining from gluten. British Society of Gastro-
enterology (BSG) guidelines indicate that during diag-
nostic endoscopy at least four biopsy specimens should 
be taken, including a duodenal bulb biopsy.26 This is in 
order to maximise diagnostic yield, as taking at least four 
biopsy specimens is shown to more than double the diag-
nostic rate in comparison to those undergoing less than 
four biopsies.24 25 Whether these guidelines are adhered 
to in clinical practice remains an important question.
There is a lack of contemporary UK data assessing if 
there is still a delay in diagnosis. Moreover, reasons for 
delay are yet to be comprehensively explored. To refine 
the diagnostic pathway for CD, these factors must be 
characterised. The aim of this UK multicentre study was 
to assess the degree of delay present in the diagnostic 
referral pathway for CD as well as determine concordance 
with biopsy guidelines. Additionally, clinician attitudes 
towards CD were explored in an attempt to characterise 
the factors influencing delay.
MATERIALS AND METHODS
Group 1: primary care presentation to biopsy completion
All patients who registered a positive endomysial anti-
body (EMA) test in primary care and were then referred 
for an endoscopy over an 18- month period (04/2014–
09/2015) in the South Yorkshire area were assessed for 
inclusion eligibility. The following data on each patient 
was collected: Hospital ID, Date of Birth, Gender, date 
of initial EMA positive blood test in primary care, date of 
referral to secondary/tertiary care, department referred 
to (gastroenterology, endoscopy, other), dates of interval 
appointments, date of endoscopy and Marsh Grade of 
duodenal biopsy specimens. For each patient, archived 
blood tests were examined to identify their first EMA 
positive result, which was recorded as the initial posi-
tive EMA result to be used in exclusion criteria. Patients 
were excluded if they were aged under 16, had a previ-
ously known diagnosis of CD, if the initial positive EMA 
result was requested by the gastroenterology outpatients 
department or other specialty (other than primary care) 
or if the patient never received a duodenal biopsy.
For the control group, all patients with a histological 
diagnosis of inflammatory bowel disease (IBD) following 
colonoscopy or flexible sigmoidoscopy were examined. 
The same data as those with histologically proven CD 
patients regarding dates of referral, appointments and 
endoscopy was collected and the same exclusion criteria 
applied. This selection criteria produced a cohort of 151 
suspected CD patients and 92 IBD patients.
Group 2: adherence to biopsy guidelines in detection of CD
Endoscopy and histology reports for all patients who 
had a duodenal biopsy for suspected CD in a 3- month 
period (11/2012–01/2013) in four UK hospitals were 
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of specimens received by histopathology, biopsy tech-
nique (single bite vs double bite), job roles of the 
endoscopist (physician, surgeon or nurse endoscopist) 
and final diagnosis were recorded for this cohort of 
1423 patients. Findings of villous atrophy were required 
for diagnosis of CD. Of those subsequently diagnosed 
with CD, patient records were checked for any previous 
non- diagnostic gastroscopies (describing a gastroscopy 
where no biopsy samples were taken) in the 5 years 
prior to diagnosis. Patients were excluded if they had 
known CD.
Group 3: case complexity analysis
An observational study was completed to compare 
patients attending a specialist CD clinic in a central 
teaching hospital (n=102) against patients attending 
a specialist IBD service in a central teaching hospital 
(n=99) and a control group of CD patients attending 
a general gastroenterology clinic at a district general 
hospital (n=36). All clinics were assessed over a 6 month 
period (09/2015–02/2016). This additional study anal-
ysed clinic appointment complexity. Both specialist 
clinics were exclusively follow- up appointments. Data 
regarding patient presenting symptoms, investigations 
(bloods, imaging, endoscopies, other), medications, 
referrals completed and planned follow- up periods was 
collected from clinic appointments.
Group 4: gastroenterology clinicians’ perspective
A questionnaire (completed between 2014 and 2015) 
aimed at assessing clinician attitudes towards CD was 
formed through use of a focus group consisting of 
a range of clinicians specialised in gastroenterology. 
Discrete choice experiments were used to establish clini-
cian preferences using multiple options and ranking for 
interventions and service provision in the comparison 
of CD with Crohn’s disease and ulcerative colitis (UC). 
Direct questioning (yes or no) was used to determine if 
the opinions of the focus group matched those gastroen-
terology clinicians.
A proforma (see online supplemental file) was 
completed through discussions with 50 gastroenterology 
registrars and consultants from across the UK. While 
questions from the proforma were asked directly, there 
was opportunity for discussion over specific options in 
order to generate qualitative data on clinician perspec-
tives. Staff grades and specialist interests of clinicians 
completing the survey were also recorded.
RESULTS
Group 1: primary care presentation to biopsy completion
Time from referral to endoscopy
Time from referral to endoscopy was 48.5 (28–89) days 
for CD patients from both centres combined. This was 
significantly longer than the wait for suspected IBD 
patients (34.5 (18–70) days; p=0.003).
Biopsy grade
Longer delays to diagnosis correlated with a significantly 
decreased Marsh Grade of duodenal biopsies. Of those 
seen within 4 weeks, 15.5% had normal- borderline 
(Marsh grade 0–3a) histology results, compared with 
44.9% seen after 4 weeks (p=0.017).
Group 2: adherence to biopsy guidelines in detection of CD
Of the 1423 patients that underwent duodenal biopsy, 97 
(6.8%) of these were subsequently diagnosed with CD. 
Regarding biopsy guidelines, 40.0% the total number 
of patients who underwent diagnostic endoscopy had at 
least four biopsies taken. The median number of biopsies 
taken per patient was 3. If guidelines to take at least four 
biopsy samples were followed, diagnosis of CD was more 
likely than if three or less biopsy samples were taken 
(10.1% vs 4.6% p<0.0001). While the median number of 
biopsies was greater in patients diagnosed with CD (4 vs 
3 p<0.0001).
Of the patients that received a CD diagnosis following 
biopsy, 12.4% had received at least one non- diagnostic 
gastroscopy in the 5 years prior to diagnosis. When 
assessing endoscopist job roles, gastroenterologists and 
nurse endoscopists were significantly more likely than 
surgeons to follow guidelines (41.5% vs 51.2% vs 18.2% 
p<0.0001) and therefore took at greater number of biop-
sies (3 vs 4 vs 2, p<0.0001). Thus, gastroenterologists and 
nurse endoscopists made a diagnosis of CD in more cases 
than surgeons (7.1% vs 6.7% vs 3.0%, p=0.10). The use of 
single bite biopsy technique compared with double bite 
resulted in an increase of 3 to 4 biopsies (p=0.02) taken 
from the second part of the duodenum (D2).
Group 3: case complexity analysis
Analysis of case complexity data (table 1) showed there 
was no significant difference in the number of times 
each presenting complaint was discussed and in the 
mean number of presenting complaints reported per 
patient between the CD group and the general clinic 
control group. When using the Bonferroni correction, 
the only symptom which specialist IBD patients experi-
enced significantly more than specialist CD patients was 
bleeding (PR/in stool).
When comparing the two specialist clinics the following 
investigations were requested significantly more in the CD 
clinic than in the IBD clinic: blood tests, genetic testing, 
gastroscopy and dual energy x- ray absorptiometry (DXA) 
scans (table 2). When using the Bonferroni correction 
to adjust for multiple analysis the p values remained less 
than 0.05, and therefore, remained significant. When 
using the Bonferroni correction, no investigations were 
requested for more patients in the IBD group compared 
with the CD group.
Table 3 shows that when using the Bonferroni correc-
tion there was no significant difference between the 
amount of times each medication type was prescribed 
between the CD and general clinic group. When 
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number of patients were prescribed immunosuppressive 
medication, disease- modifying antirheumatic drugs and 
anti- inflammatory medication.
Group 4: gastroenterology clinicians’ perspective
Of those completing the questionnaire, 64.0% (32) 
were registrar grade (trainee) and 36.0% (18) were 
consultants.
Questionnaire results revealed that 32.0% (16) of 
gastroenterologists failed to identify that CD has greater 
prevalence in adults than IBD. 36.0% (18) of gastroen-
terologists felt that doctors were not required for the 
management of CD while 16.0% (8) felt that a diagnosis 
of CD does not significantly impact patient quality of life.
Additionally, 40.8% (20) said that management of CD 
is not academically challenging. 88.0% (44) believed 
CD was less difficult to manage than IBD while 82.0% 
(42) thought CD was less significant than IBD in terms 
of resources needed to diagnose and treat. 77.1% (37) 
thought CD had less of an impact on quality of life than 
IBD.
Discussion of proforma answers with clinicians gave 
rise to a number of common themes based on perspec-
tives of CD and IBD (table 4).
DISCUSSION
This contemporary multicentre UK study demonstrates 
prolonged waiting times for endoscopy and inadequa-
cies in biopsy technique for adult patients with suspected 
CD. This objectively suggests medical inertia towards CD 
among secondary care clinicians.
Endoscopy waiting times were not in keeping with 
NICE guidelines of 6 weeks.25–27 There was a signifi-
cant negative correlation between delay till endoscopy 
and Marsh Grade of biopsy. This may suggest that with 
Table 1 Presenting symptoms at follow- up clinic appointments
Coeliac, % IBD, % P value
Adjusted
P value General, % P value Adjusted P value
Abdominal pain 36 (35.3) 45 (45.5) 0.142 – 8 (22.2) 0.148 –
Diarrhoea 37 (36.3) 52 (52.5) 0.020 0.18 9 (25.0) 0.217 –
Stool urgency 6 (5.9) 11 (11.1) 0.183 – 0 (0) 0.878 –
Bloating 20 (19.6) 11 (11.1) 0.095 – 6 (16.7) 0.698 –
Bleeding (PR/in stool) 5 (4.9) 18 (18.2) 0.003 0.027 2 (5.6) 0.137 –
Nausea/vomiting 8 (7.8) 1 (1.0) 0.721 – 2 (5.6) 0.089 –
Headache 13 (12.7) 11 (11.1) 0.019 0.171 1 (2.8) 0.649 –
Weight loss 12 (11.8) 2 (2.0) 0.007 0.063 2 (5.6) 0.289 –
Fatigue 9 (8.8) 7 (7.1) 0.647 – 3 (8.3) 0.928 –
Bold denotes a significant value with p<0.05.
IBD, inflammatory bowel disease; PR, per rectum.
Table 2 Investigations at follow- up clinic appointments
Coeliac IBD P value
Adjusted P 
value General P value
Adjusted P 
value
Bloods 83 (81.4%) 43 (43.4%) <0.001 <0.001 26 (72.2%) 0.247 –
Genetic testing 13 (12.7%) 0 (0%) <0.001* 0.002 3 (8.3%) 0.562* –
Gastroscopy 21 (20.6%) 1 (1.0%) <0.001 <0.001 6 (16.7%) 0.610 –
Colonoscopy 7 (6.9%) 16 (16.2%) 0.038 0.38 1 (2.8%) 0.680* –
Flexible sigmoidoscopy 1 (1.0%) 3 (3.0%) 0.364* – 0 (0%) 1.000* –
Capsule endoscopy 2 (2.0%) 5 (5.1%) 0.274* – 0 (0%) 1.000* –
Imaging 4 (4.0%) 10 (10.1%) 0.085 – 1 (2.8%) 1.000* –
SeHCAT test 2 (2.0%) 2 (2.0%) 1.000* – 0 (0%) 1.000* –
DXA scan 15 (14.7%) 0 (0%) <0.001 <0.001 5 (13.9%) 0.905 –
Breath tests 2 (2.0%) 3 (3.0%) 0.678* – 0 (0%) 1.000* –
Mean number of 
investigations (±SD)
2.19 (±1.41) 1.93 (±1.35) <0.001 – 1.44 (±1.23) 0.054 –
Bold denotes a significant value with p<0.05.
*One or more of the cells in 2×2 table have an expected count <5, Fisher’s exact test is used to calculate p values.
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greater wait time patients are more likely to self- impose 
a GFD, likely in attempt to achieve the improved quality 
of life from switching to a GFD,10 17 28 and increasing the 
chance of a missed diagnosis. However, there is as of yet 
no empirical evidence in the literature that greater delays 
till diagnosis mean patients are more likely to self- initiate 
a GFD. This is an area that warrants further investigation. 
It could be argued that instead those patients with a more 
florid histology were likely to be more symptomatic so 
were prioritised earlier for endoscopy. However, when 
grading urgency of endoscopy referrals in the UK, gastro-
enterologists usually only have the information provided 
on the referral letter.
The fact that in only 40.0% of endoscopies four biopsy 
samples were taken clearly represents how in the majority 
of duodenal biopsies BSG guidelines are not followed.26 
The detriment from this is clearly shown through the 
greater than doubled diagnosis rate (10.1% for four or 
more biopsies vs 4.6% for three or less) seen in endosco-
pies where the guidelines were followed. This is a clear 
example of the impact of diagnostic inertia towards CD 
on missed or delayed diagnoses and is backed by a similar 
low rate of guideline adherence (35%) in a USA based 
biopsy study.24 Patients with missed CD will go on to expe-
rience more harm through possible repeat endoscopies 
and more time spent following a gluten containing diet. 
To build on this, 12.4% of the patients diagnosed with CD 
had received a previous non- diagnostic (here meaning 
that no biopsy samples were taken) gastroscopy in the 5 
years before their diagnosis.
A strong majority of 88.0% rated IBD as having greater 
complexity than CD and 82.0% believed CD was less 
significant than IBD in terms of resources needed to 
diagnose and treat. Furthermore, 36.0% of clinicians felt 
that doctors are not required for management of CD and 
40.8% believed management of CD was not academically 
challenging. These findings suggest significant propor-
tions of gastroenterology clinicians believe CD should 
be treated with less urgency than IBD and that it is not 
a condition for which medical expertise is required, 
further building a picture of medical inertia towards the 
condition.
A systematic review estimated prevalence of 0.005%–
0.5% for UC and 0.0006%–0.32% for Crohn’s disease in 
Europe.29 However, 32.0% of clinicians incorrectly identi-
fied IBD as having greater prevalence than CD. A previous 
study compared Crohn’s disease, UC, CD patients and 
healthy controls using the Short- Form 36- Item Health 
Survey and the Hospital Anxiety and Depression Scale to 
determine quality of life scores. The total study popula-
tion was 1031, with over 200 patients included for each 
condition. Although Crohn’s disease patients reported 
the worst scores for general health, UC patients reported 
better general health than CD patients.30 The influence 
Table 4 Key qualitative themes
Key qualitative themes
1. Some clinicians had the view that CD is commonly found incidentally and that the majority of patients are asymptomatic 
and do not require medical interventions.
2. Most doctors believed that the input of a gastroenterologist is only required for confirming the diagnosis of CD. They 
suggested that all coeliac patients should then be managed in the community or by a dietitian.
3. It was often suggested that the impact on a coeliac patient’s quality of life is due to their dietary restrictions and lifestyle 
changes, rather than the burden of their symptoms. There was a suggestion that IBD patients suffer more from their 
symptoms.
4. Doctors suggested that patients with severe and persisting symptoms have a worse quality of life than those with IBD, 
however, in their opinion, there were few patients with significant symptoms of CD compared with those with IBD.
CD, coeliac disease; IBD, inflammatory bowel disease.
Table 3 Prescribed medications at clinic appointments
Coeliac, % IBD, % P value Adjusted P value
General, 
% P value Adjusted P value
Steroid 16 (15.8) 21 (21.2) 0.312 – 0 (0) 0.012* 0.084
Immunosuppression 16 (15.8) 38 (38.4) <0.001 0.002 1 (2.8) 0.043* 0.301
DMARD 1 (1.0) 21 (21.2) <0.001 <0.001 0 (0) 1.00* –
Anti- inflammatory 0 (0) 19 (19.2) <0.001 <0.001 0 (0) 1.00* –
Antispasmodic 5 (5.0) 1 (1.0) 0.212* – 0 (0) 0.326 –
Sequestrant 2 (2.0) 2 (3.0) 1.00* – 0 (0) 1.00* –
Other 11 (10.9) 11 (11.1) 0.820* – 1 (2.8) 0.288 –
Bold denotes a significant value with p<0.05.
*One or more of the cells in 2×2 table have an expected count <5, Fisher’s exact test is used to calculate p values.






























































































































6 Taylor MA, et al. BMJ Open Gastro 2021;8:e000544. doi:10.1136/bmjgast-2020-000544
Open access 
of diet on social interaction is well characterised and it has 
been shown patients with CD feel negatively controlled 
by their dietary restrictions, causing a significant impact 
on their social relationships31 in addition to their physical 
symptoms. The economic impact of purchasing gluten 
free products, which can be an average of 4.1 times more 
expensive and much less available than their gluten 
containing counterparts is also well recorded, providing 
an example of the continuing impact of the condition 
even following effective treatment.32
Despite this, 77.1% of gastroenterologists questioned 
believed CD had less of an impact on patient quality of 
life than both Crohn’s disease and UC. Moreover, 16.0% 
of gastroenterologists believed CD caused no significant 
impact on quality of life. This is a significant proportion 
considering the specialism of those surveyed and the 
presence of numerous studies characterising the effect 
of CD on patient quality of life.10 17 28 Furthermore, our 
follow- up appointment observational findings demon-
strate similar frequencies of symptom presentation 
between specialist CD and IBD clinics, with only signifi-
cantly greater (following Bonferroni correction) bleeding 
(PR/in stool), in patients with IBD. In this context, our 
findings clearly exhibit medical inertia towards CD, 
showing medical professionals do not appreciate the 
impact of the condition both alone and in comparison to 
similar conditions.
A recent study by Pritchard et al suggests that over 75% 
of CD patients have no primary care follow- up appoint-
ment,33 despite the fact that telephone follow- up clinics 
have been shown to have a positive impact of GFD adher-
ence in adults with CD.34 This combined with the finding 
that 36.0% of gastroenterologists felt that doctors were 
not required for the management of CD and that 30% 
of all CD patients have non- responsive CD (defined as 
persisting symptoms despite being on a GFD),35 suggests 
the need for an achievable, standardised national 
follow- up service for CD. Our recommendation is to call 
this ‘Coeliac UK, National Patient Charter’ and this would 
involve access to a dietitian as first point of contact, then 
access to a gastroenterologist if needed (e.g, a named 
gastroenterologist in every centre). This reflects findings 
on patient attitudes to follow up which demonstrated 
that the preferred method of follow- up for CD patients 
is to primarily see a dietician but with the option to see a 
doctor also if required.36
Dietetic services in the UK have been demonstrated 
to be inadequately resourced, with the majority of trusts 
not providing specialist clinics,37 and thus innovative 
methods for providing dietetic services are required such 
as group clinics,38 telephone clinics or digital apps. If a 
pathway could be created that is achievable and econom-
ical for the whole of the UK then this system could be 
mandated by the Coeliac National Charity perhaps under 
the auspices of a patient charter.
The recent recommendation for a no biopsy strategy for 
suspected CD patients with a 10- fold tissue transglutami-
nase IgA serology (10- fold of the upper limit of normal) 
may mitigate the delays for gastroscopy in approximately 
25% of patients.39 However, the remaining 75% may still 
be subject to the delays observed in this study unless the 
grading system is changed for this group of patients.
This is the first study to objectively demonstrate how 
medical inertia within secondary care causes diag-
nostic delay in the management of CD. We believe that 
comparing IBD and CD is akin to comparing apples and 
oranges and that this in essence is the crux of the issue. 
The medical inertia demonstrated by our study is likely 
due to the black and white view of IBD versus CD where 
all IBD cases are seen as apples needing urgent atten-
tion and all CD cases are oranges that are only referred 
down a routine pathway. Our findings suggest IBD and 
CD are not as different in clinical impact as they are 
treated. Improved knowledge of the clinical significance 
of CD may lead to more balanced referral grading among 
secondary care clinicians. Greater adherence to biopsy 
guidelines will produce higher diagnosis rates. These 
changes will contribute to reducing the vast undiagnosed 
burden of CD by producing more prompt diagnoses, 
resulting in better health outcomes.
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